1. Home
  2. RHI vs WVE Comparison

RHI vs WVE Comparison

Compare RHI & WVE Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.

Logo Robert Half Inc.

RHI

Robert Half Inc.

HOLD

Current Price

$27.26

Market Cap

2.6B

ML Signal

HOLD

Logo Wave Life Sciences Ltd.

WVE

Wave Life Sciences Ltd.

HOLD

Current Price

$7.41

Market Cap

2.4B

Sector

Health Care

ML Signal

HOLD

Company Overview

Basic Information
Metric
RHI
WVE
Founded
1948
2012
Country
United States
Singapore
Employees
N/A
N/A
Industry
Professional Services
Biotechnology: Pharmaceutical Preparations
Sector
Consumer Discretionary
Health Care
Exchange
Nasdaq
Nasdaq
Market Cap
2.6B
2.4B
IPO Year
1994
2015

Fundamental Metrics

Financial Performance
Metric
RHI
WVE
Price
$27.26
$7.41
Analyst Decision
Hold
Strong Buy
Analyst Count
7
16
Target Price
$30.33
$29.50
AVG Volume (30 Days)
2.8M
3.9M
Earning Date
04-23-2026
04-28-2026
Dividend Yield
9.03%
N/A
EPS Growth
N/A
N/A
EPS
1.33
N/A
Revenue
$5,378,506,000.00
$3,704,000.00
Revenue This Year
$1.27
N/A
Revenue Next Year
$5.95
$85.67
P/E Ratio
$19.80
N/A
Revenue Growth
N/A
149.43
52 Week Low
$21.83
$5.02
52 Week High
$48.54
$21.73

Technical Indicators

Market Signals
Indicator
RHI
WVE
Relative Strength Index (RSI) 54.76 38.42
Support Level $26.07 $6.93
Resistance Level $29.48 $7.67
Average True Range (ATR) 1.71 0.32
MACD 0.03 0.21
Stochastic Oscillator 59.13 54.96

Price Performance

Historical Comparison
RHI
WVE

About RHI Robert Half Inc.

Robert Half Inc was founded in 1948, Robert Half provides temporary, permanent, and outcome-based staffing for both in-person and remote positions in the finance and accounting, technology, legal, marketing, and administrative fields. Its subsidiary consulting arm, Protiviti, specializes in technology, risk, auditing, and compliance matters. The firm generates its sales inside the U.S. and is one of the specialized firms in the fragmented U.S. staffing industry.

About WVE Wave Life Sciences Ltd.

WAVE Life Sciences Ltd is a clinical-stage biotechnology company focused on unlocking the broad potential of RNA medicines also known as oligonucleotides, targeting ribonucleic acid (RNA), to transform human health. RNA medicines platform, PRISM, combines multiple modalities, chemistry innovation, and deep insights into human genetics to deliver scientific breakthroughs that treat both rare and prevalent disorders. Its toolkit of RNA-targeting modalities includes RNA editing, antisense silencing, and RNA interference, providing capabilities for designing and sustainably delivering candidates that optimally address disease biology. Its programs are for rare and prevalent diseases, including alpha-1 antitrypsin deficiency, obesity, Duchenne muscular dystrophy, and Huntington's disease.

Share on Social Networks: